Cabazitaxel (BioDeep_00000017396)

 

Secondary id: BioDeep_00000615072

human metabolite PANOMIX_OTCML-2023 blood metabolite Chemicals and Drugs


代谢物信息卡片


Benzenepropanoic acid, beta-[[(1,1-dimethylethoxy)carbonyl]amino]-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)-

化学式: C45H57NO14 (835.3779)
中文名称: 卡巴他赛
谱图信息: 最多检出来源 Chinese Herbal Medicine(otcml) 94.92%

分子结构信息

SMILES: CC1=C([C@@H](OC)C([C@@]2(C)[C@@]3([H])[C@](OC(C)=O)(CO4)[C@H]4C[C@@H]2OC)=O)C(C)(C)[C@@]([C@H]3OC(C5=CC=CC=C5)=O)(O)C[C@@H]1OC([C@H](O)[C@H](C6=CC=CC=C6)NC(OC(C)(C)C)=O)=O
InChI: InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1

描述信息

Cabazitaxel is a tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly. It has a role as an antineoplastic agent and a microtubule-stabilising agent. It is functionally related to a 10-deacetylbaccatin III.
Cabazitaxel is an anti-neoplastic used with the steroid medicine prednisone. Cabazitaxel is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2010.
Cabazitaxel is a Microtubule Inhibitor. The physiologic effect of cabazitaxel is by means of Microtubule Inhibition.
Cabazitaxel is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel. Therapy with cabazitaxel has been associated with a low rate of serum enzyme elevations, but has not been linked to cases of clinically apparent acute liver injury, although it can cause severe hypersensitivity infusion reactions which in some instances can be associated with acute liver injury.
Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).
Cabazitaxel is a prescription anti-cancer medicine used with the steroid medicine prednisone. Cabazitaxel is used to treat people with prostate cancer that has progressed after treatment with other anti-cancer medicines, including docetaxel. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2010.
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01C - Plant alkaloids and other natural products > L01CD - Taxanes
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.
Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.

同义名列表

45 个代谢物同义名

Benzenepropanoic acid, beta-[[(1,1-dimethylethoxy)carbonyl]amino]-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)-; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate.; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3),(1)?.0?,?]heptadec-13-en-2-yl benzoate; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate; 1-HYDROXY-7.BETA.,10.BETA.-DIMETHOXY-9-OXO-5.BETA.,20-EPOXYTAX-11-ENE-2.ALPHA.,4,13.ALPHA.-TRIYL 4-ACETATE 2-BENZOATE 13-((2R,3S)-3-(((TERT-BUTOXY)CARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE); (2alpha,5beta,7beta,10beta,13alpha)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; (2alpha,5beta,7beta,10beta,13alpha)-4-acetoxy-13-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 1-HYDROXY-7beta,10beta-DIMETHOXY-9-OXO-5beta,20-EPOXYTAX-11-ENE-2alpha,4,13alpha-TRIYL 4-ACETATE 2-BENZOATE 13-((2R,3S)-3-(((TERT-BUTOXY)CARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE); 1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate); (((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-; (2AR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,1; 1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-ene-2,4,13-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate); 4-acetoxy-13-((3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; BMQGVNUXMIRLCK-OAGWZNDDSA-N; CABAZITAXEL ACETONATE [JAN]; CABAZITAXEL [ORANGE BOOK]; Cabazitaxel [USAN:INN]; CABAZITAXEL [EMA EPAR]; Cabazitaxel (USAN/INN); Cabazitaxel (Jevtana); cabazitaxel acetonate; Cabazitaxel Injection; CABAZITAXEL [WHO-DD]; CABAZITAXEL [MART.]; CABAZITAXEL [VANDF]; CABAZITAXEL (MART.); CABAZITAXEL [USAN]; CABAZITAXEL [INN]; CABAZITAXEL [MI]; UNII-51F690397J; Taxoid XRP6258; Cabazitaxelum; Jevtana (TN); kabazitaxel; Jevtana Kit; Cabazitaxel; 51F690397J; L01CD04; Jevanta; jevtana; XRP6258; RPR-116258A



数据库引用编号

12 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

3 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Sunyi Wu, Linwei Lu, Jianfen Zhou, Danni Ran, Songli Wang, Qianzhu Xu, Weixia Xu, Jun Wang, Yu Liu, Cao Xie, Zimiao Luo, Weiyue Lu. All-stage targeted therapy for glioblastoma based on lipid membrane coated cabazitaxel nanocrystals. Journal of controlled release : official journal of the Controlled Release Society. 2022 05; 345(?):685-695. doi: 10.1016/j.jconrel.2022.03.047. [PMID: 35346767]
  • Giorgia Gurioli, Vincenza Conteduca, Nicole Brighi, Emanuela Scarpi, Umberto Basso, Giuseppe Fornarini, Alessandra Mosca, Maurizio Nicodemo, Giuseppe Luigi Banna, Cristian Lolli, Giuseppe Schepisi, Giorgia Ravaglia, Isabella Bondi, Paola Ulivi, Ugo De Giorgi. Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel. BMC medicine. 2022 01; 20(1):48. doi: 10.1186/s12916-022-02244-0. [PMID: 35101049]
  • Tianyang Ren, Xuehua Zheng, Ruixue Bai, Yuehui Yang, Lingyan Jian. Bioadhesive poly(methyl vinyl ether-co-maleic anhydride)-TPGS copolymer modified PLGA/lipid hybrid nanoparticles for improving intestinal absorption of cabazitaxel. International journal of pharmaceutics. 2022 Jan; 611(?):121301. doi: 10.1016/j.ijpharm.2021.121301. [PMID: 34793933]
  • Elahehnaz Parhizkar, Soliman Mohammadi Samani, Amirhossein Sakhteman, Saeid Daneshamouz, Golnaz Parhizkar, Fatemeh Ahmadi. Synthesis, cytotoxicity assay, pharmacokinetics, biodistribution and modeling study of cabazitaxel-dextran nanoconjugates: targeted vs non targeted delivery. Colloids and surfaces. B, Biointerfaces. 2022 Jan; 209(Pt 2):112187. doi: 10.1016/j.colsurfb.2021.112187. [PMID: 34837858]
  • Jie Li, Huamin Zeng, Yu You, Rongrong Wang, Tiantian Tan, Weiming Wang, Liyan Yin, Zhaowu Zeng, Yiying Zeng, Tian Xie. Active targeting of orthotopic glioma using biomimetic liposomes co-loaded elemene and cabazitaxel modified by transferritin. Journal of nanobiotechnology. 2021 Sep; 19(1):289. doi: 10.1186/s12951-021-01048-3. [PMID: 34565383]
  • Motohiro Fujiwara, Takeshi Yuasa, Shotaro Yasuoka, Yoshinobu Komai, Tomohiko Oguchi, Ryo Fujiwara, Noboru Numao, Shinya Yamamoto, Junji Yonese. Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer. Cancer chemotherapy and pharmacology. 2021 09; 88(3):525-531. doi: 10.1007/s00280-021-04304-3. [PMID: 34110449]
  • Shang Eun Park, Naglaa Salem El-Sayed, Kiumars Shamloo, Sandeep Lohan, Sumit Kumar, Muhammad Imran Sajid, Rakesh Kumar Tiwari. Targeted Delivery of Cabazitaxel Using Cyclic Cell-Penetrating Peptide and Biomarkers of Extracellular Matrix for Prostate and Breast Cancer Therapy. Bioconjugate chemistry. 2021 08; 32(8):1898-1914. doi: 10.1021/acs.bioconjchem.1c00319. [PMID: 34309357]
  • Seiji Hishida, Kyojiro Kawakami, Yasunori Fujita, Taku Kato, Manabu Takai, Koji Iinuma, Keita Nakane, Tomohiro Tsuchiya, Takuya Koie, Yuri Miura, Masafumi Ito, Kosuke Mizutani. Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer. The Prostate. 2021 06; 81(9):592-602. doi: 10.1002/pros.24138. [PMID: 33905554]
  • Manabu Takai, Seiichi Kato, Masahiro Nakano, Shota Fujimoto, Koji Iinuma, Takashi Ishida, Mitsuhiro Taniguchi, Masayoshi Tamaki, Masahiro Uno, Yoshito Takahashi, Hisao Komeda, Takuya Koie. Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration-resistant prostate cancer: A local experience of a multicenter retrospective study. Asia-Pacific journal of clinical oncology. 2021 Jun; 17(3):238-244. doi: 10.1111/ajco.13441. [PMID: 32970933]
  • Sofie Snipstad, Ýrr Mørch, Einar Sulheim, Andreas Åslund, André Pedersen, Catharina de Lange Davies, Rune Hansen, Sigrid Berg. Sonopermeation Enhances Uptake and Therapeutic Effect of Free and Encapsulated Cabazitaxel. Ultrasound in medicine & biology. 2021 05; 47(5):1319-1333. doi: 10.1016/j.ultrasmedbio.2020.12.026. [PMID: 33549379]
  • Pallavi Chand, Hitesh Kumar, Nihal Badduri, N Vishal Gupta, Vidya G Bettada, SubbaRao V Madhunapantula, Siddharth S Kesharwani, Surajit Dey, Vikas Jain. Design and evaluation of cabazitaxel loaded NLCs against breast cancer cell lines. Colloids and surfaces. B, Biointerfaces. 2021 Mar; 199(?):111535. doi: 10.1016/j.colsurfb.2020.111535. [PMID: 33360926]
  • Abhinav Khanna, Luke P O'Connor, Prithvi B Murthy, Darren J Bryk, Michele Fascelli, Kyle Ericson, Nitin K Yerram, Samuel C Haywood, Robert Abouassaly. Contemporary management of advanced prostate cancer: an evolving landscape. Clinical advances in hematology & oncology : H&O. 2021 Feb; 19(2):108-118. doi: NULL. [PMID: 33596192]
  • Zhen Qu, Yuning Ren, Hongyu Shen, Huihui Wang, Lijie Shi, Deyong Tong. Combination Therapy of Metastatic Castration-Recurrent Prostate Cancer: Hyaluronic Acid Decorated, Cabazitaxel-Prodrug and Orlistat Co-Loaded Nano-System. Drug design, development and therapy. 2021; 15(?):3605-3616. doi: 10.2147/dddt.s306684. [PMID: 34447241]
  • Guarionex J DeCastro, Wilson Sui, Jamie S Pak, Shing M Lee, Dara Holder, Max M Kates, Renu K Virk, Charles G Drake, Christopher B Anderson, Bridget James, Cory T Abate-Shen, James M McKiernan. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder. The Journal of urology. 2020 Aug; 204(2):247-253. doi: 10.1097/ju.0000000000000919. [PMID: 32118506]
  • Yougan Chen, Yuanyuan Deng, Chenyao Zhu, Congming Xiang. Anti prostate cancer therapy: Aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020 Jul; 127(?):110181. doi: 10.1016/j.biopha.2020.110181. [PMID: 32416561]
  • Zhong Wan, Fangyuan Xie, Liang Wang, Guoqing Zhang, Hai Zhang. Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer. International journal of nanomedicine. 2020; 15(?):5333-5344. doi: 10.2147/ijn.s258856. [PMID: 32801692]
  • Gregory Carbonetti, Cynthia Converso, Timothy Clement, Changwei Wang, Lloyd C Trotman, Iwao Ojima, Martin Kaczocha. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth. The Prostate. 2020 01; 80(1):88-98. doi: 10.1002/pros.23921. [PMID: 31661167]
  • Mamoru Hashimoto, Takafumi Minami, Mamoru Hamaguchi, Saizo Fujimoto, Tomoki Takahashi, Takashi Kikuchi, Shogo Adomi, Eri Banno, Takayuki Ohzeki, Nobutaka Shimizu, Yasunori Mori, Masahiro Nozawa, Kazuhiro Nose, Kazuhiro Yoshimura, Hirotsugu Uemura. Reactivation of latent tuberculosis infection induced by cabazitaxel in a patient with prostate cancer: A case report. Medicine. 2019 Dec; 98(51):e18436. doi: 10.1097/md.0000000000018436. [PMID: 31861013]
  • Chester A Metcalf, Sonke Svenson, Jungyeon Hwang, Snehlata Tripathi, Geeti Gangal, Sujan Kabir, Douglas Lazarus, Roderic Cole, Beata Sweryda-Krawiec, Pochi Shum, Donna Brown, Roy I Case, Derek van der Poll, Ellen Rohde, Stephanie Harlfinger, Chi-Hse Teng, Scott Eliasof. Discovery of a Novel Cabazitaxel Nanoparticle-Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects Using a β-Cyclodextrin-PEG Copolymer Based Delivery Platform. Journal of medicinal chemistry. 2019 11; 62(21):9541-9559. doi: 10.1021/acs.jmedchem.9b00892. [PMID: 31593466]
  • Nagavendra Kommineni, Raju Saka, Upendra Bulbake, Wahid Khan. Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer. Chemistry and physics of lipids. 2019 11; 224(?):104707. doi: 10.1016/j.chemphyslip.2018.11.009. [PMID: 30521787]
  • Yu Zheng, Ting Lan, Di Wei, Geng Zhang, Guangdong Hou, Jiarui Yuan, Fei Yan, Fuli Wang, Ping Meng, Xiaojian Yang, Guo Chen, Zheng Zhu, Zifan Lu, Wei He, Jianlin Yuan. Coupling the near-infrared fluorescent dye IR-780 with cabazitaxel makes renal cell carcinoma chemotherapy possible. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2019 Aug; 116(?):109001. doi: 10.1016/j.biopha.2019.109001. [PMID: 31146114]
  • Vincenza Conteduca, Elena Castro, Daniel Wetterskog, Emanuela Scarpi, Anuradha Jayaram, Nuria Romero-Laorden, David Olmos, Giorgia Gurioli, Cristian Lolli, Maria Isabel Sáez, Javier Puente, Giuseppe Schepisi, Samanta Salvi, Anna Wingate, Ana Medina, Rosa Querol-Niñerola, Mercedes Marin-Aguilera, Jose Angel Arranz, Giuseppe Fornarini, Umberto Basso, Begoña Mellado, Enrique Gonzalez-Billalabeitia, Gerhardt Attard, Ugo De Giorgi. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. European journal of cancer (Oxford, England : 1990). 2019 07; 116(?):158-168. doi: 10.1016/j.ejca.2019.05.007. [PMID: 31200322]
  • Yi-Ying Zeng, Yi-Jun Zeng, Na-Na Zhang, Chen-Xi Li, Tian Xie, Zhao-Wu Zeng. The Preparation, Determination of a Flexible Complex Liposome Co-Loaded with Cabazitaxel and β-Elemene, and Animal Pharmacodynamics on Paclitaxel-Resistant Lung Adenocarcinoma. Molecules (Basel, Switzerland). 2019 Apr; 24(9):. doi: 10.3390/molecules24091697. [PMID: 31052317]
  • Masaki Shiota, Eiji Kashiwagi, Tomohiko Murakami, Ario Takeuchi, Kenjiro Imada, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer. Urologic oncology. 2019 03; 37(3):180.e19-180.e24. doi: 10.1016/j.urolonc.2018.10.020. [PMID: 30446464]
  • Akira Kageyama, Yusuke Nakazawa, Naomi Ando, Dai Harada, Masaki Kitamura, Takashi Kawakubo, Koji Asano. [Identification of the Risk Factors for Cabazitaxel-Induced Neutropenia with Preventive Administration of Pegfilgrastim]. Gan to kagaku ryoho. Cancer & chemotherapy. 2019 Feb; 46(2):279-281. doi: NULL. [PMID: 30914534]
  • Markus Fusser, Anders Øverbye, Abhilash D Pandya, Ýrr Mørch, Sven Even Borgos, Wanja Kildal, Sofie Snipstad, Einar Sulheim, Karianne Giller Fleten, Hanne Arenberg Askautrud, Olav Engebraaten, Kjersti Flatmark, Tore Geir Iversen, Kirsten Sandvig, Tore Skotland, Gunhild M Mælandsmo. Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. Journal of controlled release : official journal of the Controlled Release Society. 2019 01; 293(?):183-192. doi: 10.1016/j.jconrel.2018.11.029. [PMID: 30529259]
  • Yating Sun, Yarong Zhao, Shanshan Teng, Fei Hao, Huan Zhang, Fanchao Meng, Xiuting Zhao, Xiaolong Zheng, Ye Bi, Yicheng Yao, Robert J Lee, Lesheng Teng. Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy. International journal of nanomedicine. 2019; 14(?):135-148. doi: 10.2147/ijn.s181296. [PMID: 30613142]
  • Zhongjie Lu, Tongyu Li, Lulu Ren, Liqian Zhou, Jianqin Wan, Jiaping Wu, Yiting Qiao, Haiyang Xie, Shusen Zheng, Hangxiang Wang. Chemical Derivatization of the Anticancer Agent Cabazitaxel Using a Polyunsaturated Fatty Acid for Safe Drug Delivery In Vivo. Journal of biomedical nanotechnology. 2018 Nov; 14(11):1853-1865. doi: 10.1166/jbn.2018.2625. [PMID: 30165923]
  • Yang Liu, Bin Xie, Lin Li, Xinyu Zhang, Yu Zhang, Haibing He, Tian Yin, Xing Tang, Cuifang Cai, Jingxin Gou. PEGylated lipid microspheres loaded with cabazitaxel for intravenous administration: stability, bioavailability, antitumor efficacy, and toxicity. Drug delivery and translational research. 2018 10; 8(5):1365-1379. doi: 10.1007/s13346-018-0562-0. [PMID: 30019282]
  • Caochuan Feng, Xiaoxiong Han, Lili Chi, Jing Sun, Feirong Gong, Yaling Shen. Synthesis, characterization, and in vitro evaluation of TRAIL-modified, cabazitaxel -loaded polymeric micelles for achieving synergistic anticancer therapy. Journal of biomaterials science. Polymer edition. 2018 10; 29(14):1729-1744. doi: 10.1080/09205063.2018.1483616. [PMID: 29851539]
  • Niven Mehra, David Dolling, Semini Sumanasuriya, Rossitza Christova, Lorna Pope, Suzanne Carreira, George Seed, Wei Yuan, Jane Goodall, Emma Hall, Penny Flohr, Gunther Boysen, Diletta Bianchini, Oliver Sartor, Mario A Eisenberger, Karim Fizazi, Stephane Oudard, Mustapha Chadjaa, Sandrine Macé, Johann S de Bono. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). European urology. 2018 09; 74(3):283-291. doi: 10.1016/j.eururo.2018.02.013. [PMID: 29500065]
  • Tianyang Ren, Jingxin Gou, Wanxiao Sun, Xiaoguang Tao, Xinyi Tan, Puxiu Wang, Yu Zhang, Haibing He, Tian Yin, Xing Tang. Entrapping of Nanoparticles in Yeast Cell Wall Microparticles for Macrophage-Targeted Oral Delivery of Cabazitaxel. Molecular pharmaceutics. 2018 07; 15(7):2870-2882. doi: 10.1021/acs.molpharmaceut.8b00357. [PMID: 29863879]
  • Tianyang Ren, Qian Wang, Ying Xu, Lin Cong, Jingxin Gou, Xiaoguang Tao, Yu Zhang, Haibing He, Tian Yin, Haotian Zhang, Yan Zhang, Xing Tang. Enhanced oral absorption and anticancer efficacy of cabazitaxel by overcoming intestinal mucus and epithelium barriers using surface polyethylene oxide (PEO) decorated positively charged polymer-lipid hybrid nanoparticles. Journal of controlled release : official journal of the Controlled Release Society. 2018 01; 269(?):423-438. doi: 10.1016/j.jconrel.2017.11.015. [PMID: 29133120]
  • Hangxiang Wang, Zhongjie Lu, Lijiang Wang, Tingting Guo, Jiaping Wu, Jianqin Wan, Liqian Zhou, Hui Li, Zhen Li, Donghai Jiang, Penghong Song, Haiyang Xie, Lin Zhou, Xiao Xu, Shusen Zheng. New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity. Cancer research. 2017 12; 77(24):6963-6974. doi: 10.1158/0008-5472.can-17-0984. [PMID: 29055017]
  • Joseph Bteich, Simon A McManus, Mark J Ernsting, Mohammed Z Mohammed, Robert K Prud'homme, Kenneth K Sokoll. Using Flash Nanoprecipitation To Produce Highly Potent and Stable Cellax Nanoparticles from Amphiphilic Polymers Derived from Carboxymethyl Cellulose, Polyethylene Glycol, and Cabazitaxel. Molecular pharmaceutics. 2017 11; 14(11):3998-4007. doi: 10.1021/acs.molpharmaceut.7b00670. [PMID: 28945432]
  • Mohammad Kazem Khoeeniha, Mehdi Esfandyari-Manesh, Hossein Behrouz, Mohsen Amini, Behrang Shiri Varnamkhasti, Fatemeh Atyabi, Rassoul Dinarvand. Targeted Delivery of Cabazitaxel by Conjugation to Albumin-PEG-folate Nanoparticles Using a Cysteine-acrylate Linker and Simple Synthesis Conditions. Current drug delivery. 2017; 14(8):1120-1129. doi: 10.2174/1567201814666161122150302. [PMID: 27875950]
  • Guoming Zhou, Xiangyu Jin, Ping Zhu, J U Yao, Yingxin Zhang, Lesheng Teng, Robert J Lee, Xiaomin Zhang, Wei Hong. Human Serum Albumin Nanoparticles as a Novel Delivery System for Cabazitaxel. Anticancer research. 2016 Apr; 36(4):1649-56. doi: NULL. [PMID: 27069142]
  • Giuseppe Di Lorenzo, Sergio Bracarda, Donatello Gasparro, Angela Gernone, Caterina Messina, Vittorina Zagonel, Livio Puglia, Davide Bosso, Davide Dondi, Guru Sonpavde, Giuseppe Lucarelli, Sabino De Placido, Carlo Buonerba. Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Medicine. 2016 Jan; 95(2):e2299. doi: 10.1097/md.0000000000002299. [PMID: 26765406]
  • Xiaoxiong Han, Dan Chen, Jing Sun, Jinsong Zhou, Duan Li, Feirong Gong, Yaling Shen. A novel cabazitaxel-loaded polymeric micelle system with superior in vitro stability and long blood circulation time. Journal of biomaterials science. Polymer edition. 2016; 27(7):626-42. doi: 10.1080/09205063.2016.1146980. [PMID: 26914063]
  • Na Qu, Robert J Lee, Yating Sun, Guangsheng Cai, Junyang Wang, Mengqiao Wang, Jiahui Lu, Qingfan Meng, Lirong Teng, Di Wang, Lesheng Teng. Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer. International journal of nanomedicine. 2016; 11(?):3451-9. doi: 10.2147/ijn.s105420. [PMID: 27555767]
  • Seng Chuan Tang, Anita Kort, Ka Lei Cheung, Hilde Rosing, Tatsuki Fukami, Selvi Durmus, Els Wagenaar, Jeroen J M A Hendrikx, Miki Nakajima, Bart J M van Vlijmen, Jos H Beijnen, Alfred H Schinkel. P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice. Molecular pharmaceutics. 2015 Oct; 12(10):3714-23. doi: 10.1021/acs.molpharmaceut.5b00470. [PMID: 26317243]
  • Taku Kato, Kosuke Mizutani, Koji Kameyama, Kyojiro Kawakami, Yasunori Fujita, Keita Nakane, Yusuke Kanimoto, Hidetoshi Ehara, Hiroyasu Ito, Mitsuru Seishima, Takashi Deguchi, Masafumi Ito. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer. Urologic oncology. 2015 Sep; 33(9):385.e15-20. doi: 10.1016/j.urolonc.2015.04.019. [PMID: 26027763]
  • Pedram Kharaziha, Dimitris Chioureas, Dorothea Rutishauser, George Baltatzis, Lena Lennartsson, Pedro Fonseca, Alireza Azimi, Kjell Hultenby, Roman Zubarev, Anders Ullén, Jeffrey Yachnin, Sten Nilsson, Theocharis Panaretakis. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget. 2015 Aug; 6(25):21740-54. doi: 10.18632/oncotarget.3226. [PMID: 25844599]
  • Laurence Ridoux, Dorothée R Sémiond, Carine Vincent, Hélène Fontaine, Christine Mauriac, Ger-Jan Sanderink, Corina Oprea, Lindsay Kelly, Sally Clive. A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Anti-cancer drugs. 2015 Mar; 26(3):350-8. doi: 10.1097/cad.0000000000000185. [PMID: 25462133]
  • John Sarantopoulos, Alain C Mita, James L Wade, John C Morris, Olivier Rixe, Monica M Mita, Jean-François Dedieu, Claudine Wack, Laurent Kassalow, A Craig Lockhart. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel. Cancer chemotherapy and pharmacology. 2014 Dec; 74(6):1113-24. doi: 10.1007/s00280-014-2572-z. [PMID: 25307552]
  • Pierre Maison-Blanche, Shaker Dakhil, Ari Baron, Sylvie Rottey, Fred Millard, Gedske Daugaard, Jean-Pascal Machiels, William Conkright, Sunil Sharma, Patricia M M B Soetekouw, Jeffrey Yachnin, Lisa Sengeløv, Peter Van Veldhuizen, Sanjiv S Agarwala, Dorothée Sémiond, Mustapha Chadjaa, Liji Shen, James L Wade. An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2014 Jun; 73(6):1241-52. doi: 10.1007/s00280-014-2460-6. [PMID: 24718982]
  • Yanjie Shao, Chungang Zhang, Qing Yao, Yueqi Wang, Bin Tian, Xing Tang, Yanjiao Wang. Improving cabazitaxel chemical stability in parenteral lipid emulsions using cholesterol. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2014 Feb; 52(?):1-11. doi: 10.1016/j.ejps.2013.09.024. [PMID: 24153395]
  • Yun-rong Jing, Wei Zhou, Wan-liang Li, Lin-xiang Zhao, Yong-feng Wang. The synthesis of novel taxoids for oral administration. Bioorganic & medicinal chemistry. 2014 Jan; 22(1):194-203. doi: 10.1016/j.bmc.2013.11.037. [PMID: 24332858]
  • Patricia Vrignaud, Dorothée Sémiond, Pascale Lejeune, Hervé Bouchard, Loreley Calvet, Cecile Combeau, Jean-François Riou, Alain Commerçon, François Lavelle, Marie-Christine Bissery. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Jun; 19(11):2973-83. doi: 10.1158/1078-0432.ccr-12-3146. [PMID: 23589177]
  • A Kort, M J X Hillebrand, G A Cirkel, E E Voest, A H Schinkel, H Rosing, J H M Schellens, J H Beijnen. Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2013 Apr; 925(?):117-23. doi: 10.1016/j.jchromb.2013.02.034. [PMID: 23542607]
  • Peter de Bruijn, Anne-Joy M de Graan, Annemieke Nieuweboer, Ron H J Mathijssen, Mei-Ho Lam, Ronald de Wit, Erik A C Wiemer, Walter J Loos. Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding. Journal of pharmaceutical and biomedical analysis. 2012 Feb; 59(?):117-22. doi: 10.1016/j.jpba.2011.10.010. [PMID: 22079047]